Tekcapital PLC (LON:TEK) soared on Monday as it believes its portfolio firm Belluscura could benefit from a new US policy.
The US Food and Drug Administration has issued new guidance to help expand the availability of ventilators as well as other respiratory devices during this pandemic.
READ: Tekcapital soars as Belluscura files patent for oxygen system to treat respiratory illnesses brought on by coronavirus
According to intellectual property firm Tekcapital, the new rules are “potentially relevant” to Belluscura, which develops oxygen-based treatment platforms.
Last week, the biotech firm filed a patent for a portable oxygen enrichment system to treat respiratory illnesses brought on by infections, such as coronavirus.
Shares rocketed 72% to 8.15p on Monday afternoon.